Opus Genetics, Company Insiders
IRD Stock | 1.11 0.06 5.71% |
Opus Genetics,'s insiders are aggressively buying. The analysis of insiders' sentiment of trading Opus Genetics, stock suggests that all insiders are extremely bullish at this time. Opus Genetics, employs about 14 people. The company is managed by 8 executives with a total tenure of roughly 33 years, averaging almost 4.0 years of service per executive, having 1.75 employees per reported executive.
Opus Genetics,'s Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-11-18 | George Magrath | Acquired 9706 @ 1.02 | View | ||
2024-11-15 | George Magrath | Acquired 90294 @ 1.01 | View |
Monitoring Opus Genetics,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Opus |
Opus Genetics, Workforce Comparison
Opus Genetics, is currently regarded as number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 559. Opus Genetics, holds roughly 14.0 in number of employees claiming about 2.5% of stocks in Biotechnology industry.
Opus Genetics, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Opus Genetics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Opus Genetics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Opus Genetics, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yerxa Benjamin R over a week ago Acquisition by Yerxa Benjamin R of 10000 shares of Opus Genetics, at 0.9834 subject to Rule 16b-3 | ||
Magrath George over a week ago Acquisition by Magrath George of 9706 shares of Opus Genetics, at 1.0244 subject to Rule 16b-3 | ||
Magrath George over a week ago Acquisition by Magrath George of 90294 shares of Opus Genetics, at 1.0102 subject to Rule 16b-3 | ||
Yerxa Benjamin R over two weeks ago Acquisition by Yerxa Benjamin R of 332800 shares of Opus Genetics, subject to Rule 16b-3 | ||
Magrath George over three weeks ago Disposition of 37050 shares by Magrath George of Opus Genetics, at 1.18 subject to Rule 16b-3 | ||
Bennett Jean over a month ago Insider Trading | ||
Bennett Jean over a month ago Insider Trading |
Opus Genetics, Notable Stakeholders
An Opus Genetics, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Opus Genetics, often face trade-offs trying to please all of them. Opus Genetics,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Opus Genetics,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MBA MD | CEO Director | Profile | |
Erik Sims | Director Controller | Profile | |
Joseph MBA | Chief Officer | Profile | |
Bernhard MBA | Senior Secretary | Profile | |
Ashwath Jayagopal | Chief Officer | Profile | |
Bindu Manne | Head Commercialization | Profile | |
MAcc CPA | Senior Finance | Profile | |
Nirav CFA | Chief Officer | Profile |
About Opus Genetics, Management Performance
The success or failure of an entity such as Opus Genetics, often depends on how effective the management is. Opus Genetics, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Opus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Opus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Opus Genetics, is entity of United States. It is traded as Stock on NASDAQ exchange.
Please note, the presentation of Opus Genetics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Opus Genetics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Opus Genetics,'s management manipulating its earnings.
Opus Genetics, Workforce Analysis
Traditionally, organizations such as Opus Genetics, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Opus Genetics, within its industry.Opus Genetics, Manpower Efficiency
Return on Opus Genetics, Manpower
Revenue Per Employee | 1.4M | |
Revenue Per Executive | 2.4M | |
Net Loss Per Employee | 713.3K | |
Net Loss Per Executive | 1.2M | |
Working Capital Per Employee | 3.6M | |
Working Capital Per Executive | 6.2M |
Complementary Tools for Opus Stock analysis
When running Opus Genetics,'s price analysis, check to measure Opus Genetics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics, is operating at the current time. Most of Opus Genetics,'s value examination focuses on studying past and present price action to predict the probability of Opus Genetics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics,'s price. Additionally, you may evaluate how the addition of Opus Genetics, to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |